OraSure Technologies reported Q4 2019 net revenues of $49.7 million, a 1% decrease from Q4 2018. Net income for the quarter was $2.4 million, or $0.04 per share.
Net revenues for the fourth quarter of 2019 were $49.7 million, a 1% decrease from the fourth quarter of 2018.
Net product revenues were $47.2 million, a 5% increase from the fourth quarter of 2018.
International sales of the Company’s OraQuick® HIV products increased 123% compared to the fourth quarter of 2018.
Total microbiome product and service revenues in the fourth quarter of 2019 were $4.4 million compared to $1.9 million in the fourth quarter of 2018.
The Company expects consolidated net revenues for the year ended December 31, 2020 to range from $145.0 million to $155.0 million and is projecting a net loss of $0.07 to $0.10 per share.
Analyze how earnings announcements historically affect stock price performance